Premium
Dichloro‐[1‐(hydroxyphenyl)‐2‐phenylethylenediamine]platinum(II) Complexes: Testing on the Human Ovarian Cancer Cell Lines NIH: OVCAR 3 and SK OV 3
Author(s) -
Bernhardt Günther,
Müller Richard,
Gust Ronald,
Reile Herta,
Keller Christoph,
Spruß Thilo,
Schönenberger Helmut
Publication year - 1992
Publication title -
archiv der pharmazie
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.468
H-Index - 61
eISSN - 1521-4184
pISSN - 0365-6233
DOI - 10.1002/ardp.19923250208
Subject(s) - ethylenediamine , cisplatin , chemistry , cell culture , platinum , ovarian cancer , stereochemistry , cancer research , cancer , biochemistry , medicine , chemotherapy , biology , organic chemistry , genetics , catalysis
The diastereoisomeric dichloro‐[1‐(2‐, 3‐ and 4‐hydroxyphenyl)‐2‐phenyl‐ethylenediamine]platinum(II) complexes were tested on two human ovarian cancer cell lines NIH: OVCAR‐3 and SK‐OV‐3, both resistant against cisplatin. Dichloro‐[ threo ‐1‐(3‐hydroxyphenyl)‐2‐phenylethylenediamine]platinum(II) ( threo ‐ 5 ‐PtCl 2 ) proved to be the most active representative of the new series, producing cytocidal effects at a concentration range of 2. 5 to 5. 0 μM on the NIH: OVCAR‐3 cell line. On the more resistant SK‐OV‐3 cell line, threo ‐ 5 ‐PtCl 2 was only moderately active, while in combination with BSO, a GSH level lowering compound, threo ‐ 5 ‐PtCl 2 showed a strong synergistic effect.